This phase II trial is evaluating lenalidomide as a maintenance therapy for patients with high risk multiple myeloma who have receivied an allogenic stem cell transplant.
This trial is treating patients with Multiple Myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Lenalidomide consolidation post allogeneic stem cell transplant for patients with high risk multiple myeloma failing to achieve stringent Complete Response
This study proposes to explore the safety and efficacy of lenalidomide consolidation post allogeneic stem cell transplant in patients with high risk multiple myeloma who fail to achieve stringent complete response.
Who is it for?
You may be eligible to join this study if you are aged 18 years or above and have a diagnosis of multiple myeloma for which you plan to undergo stem cell transplantation.
All participants in this study will commence treatment with Lenalidomide 180 days after stem cell transplantation. Lenalidomide is a chemotherapy drug which is taken orally at an initial dose of 10mg daily for 21 of 28 days (1 cycle), increasing to 15mg for subsequent treatment cycles. This will be taken in combination with weekly oral dexamethasone for the first 2 cycles. Treatment will continue until any of the following occurs:
a. Unacceptable toxicity/adverse event that may cause severe or permanent harm which rule out continuation of the study drug
b. Relapse/progressive disease and alternative myeloma treatment is required
d. The study may also be terminated early if safety concerns emerge with this treatment
Participants will be regularly monitored until relapse or end of treatment in order to evaluate the safety and tolerability of the treatment, as well as disease response.
Not Recruiting Hospitals Read More